ReviewJournal of clinical medicine2023
Coronary No-Reflow after Primary Percutaneous Coronary Intervention-Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Excimer laser angioplasty for acute coronary occlusion: a stratified meta-analysis of efficacy against aspiration thrombectomy and conventional PCI.Lasers in medical science · 2026Pooled it
- Pan-immune-inflammation value for risk stratification of adverse cardiovascular outcomes in acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- [Angiographic result with the use of adenosine before percutaneous coronary intervention in pharmacoinvasive therapy].Revista medica del Instituto Mexicano del Seguro Social · 2024Trial
- Admission serum mitochondrial DNA relative abundance is associated with angiographic no-reflow or slow-flow after primary percutaneous coronary intervention in STEMI.Journal of thrombosis and thrombolysis · 2026Article
- Intravascular Imaging to Predict the Coronary No-Reflow and Slow-Flow Phenomena: Advances and Perspectives.Reviews in cardiovascular medicine · 2026Review
- The Hidden Burden of Depression in STEMI: Effects on Early Complications and 12-Month MACCE.Diagnostics (Basel, Switzerland) · 2026Article
- Extracellular Traps in Coronary Thrombus Aspirates from Patients with ST-Elevation Myocardial Infarction.International journal of molecular sciences · 2026Article
- Inflammation-Based C-Reactive Protein-to-Albumin Ratio for No-Reflow Prediction in STEMI.Biomedicines · 2026Article
- A single-center observational study on the impact of intravascular ultrasound-detected attenuated plaque on coronary microvascular dysfunction following percutaneous coronary intervention.The international journal of cardiovascular imaging · 2026Observational
- Machine Learning-Based Prediction of Long-Term Mortality in STEMI Patients Using Clinical, Laboratory, and Inflammatory-Metabolic Indices.Journal of clinical medicine · 2026Article
- The mechanism and clinical research of vagus nerve electrical stimulation in the treatment of myocardial ischemia-reperfusion injury.iScience · 2026Review
- Admission EASIX Score Predicts Coronary No-Reflow and In-Hospital Mortality in STEMI Patients Undergoing Primary PCI.Journal of clinical medicine · 2026Article
- Platelets as Central Modulators of Post-Cardiac Arrest Syndrome: Mechanisms and Therapeutic Implications.Biomolecules · 2026Review
- Predictive value of the NORPACS score for malignant ventricular arrhythmias in STEMI patients undergoing primary PCI.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- A NET-associated immunothrombotic phenotype is associated with coronary no-reflow and myocardial injury after primary PCI in ST-segment elevation myocardial infarction: a real-world translational cohort.Frontiers in immunology · 2026Article
- Predictive value of Index of Cardiac Electrophysiological Balance (ICEB) for ischemia-reperfusion injury following coronary artery angioplasty.American journal of translational research · 2026Article
- Left ventricular blood flow kinetic energy by 4D flow magnetic resonance imaging in patients with acute myocardial infarction after revascularization.Quantitative imaging in medicine and surgery · 2026Article
- Article
- Thrombectomy in acute myocardial infarction: Current evidence, challenges, and emerging technologies.World journal of clinical cases · 2025Review
- Thermodynamic Biomarkers of Neuroinflammation: Nanothermometry, Energy-Stress Dynamics, and Predictive Entropy in Glial-Vascular Networks.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary no-reflow (CNR) is a frequent phenomenon that develops in patients with ST-segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is highly dynamic, develops gradually (over hours) and persists for days to weeks after reperfusion. Microvascular obstruction (MVO) developing as a consequence of myocardial ischemia, distal embolization and reperfusion-related injury is the main pathophysiological mechanism of CNR. The frequency of CNR or MVO after primary PCI differs widely depending on the sensitivity of the tools used for diagnosis and timing of examination. Coronary angiography is readily available and most convenient to diagnose CNR but it is highly conservative and underestimates the true frequency of CNR. Cardiac magnetic resonance (CMR) imaging is the most sensitive method to diagnose MVO and CNR that provides information on the presence, localization and extent of MVO. CMR imaging detects intramyocardial hemorrhage and accurately estimates the infarct size. MVO and CNR markedly negate the benefits of reperfusion therapy and contribute to poor clinical outcomes including adverse remodeling of left ventricle, worsening or new congestive heart failure and reduced survival. Despite extensive research and the use of therapies that target almost all known pathophysiological mechanisms of CNR, no therapy has been found that prevents or reverses CNR and provides consistent clinical benefit in patients with STEMI undergoing reperfusion. Currently, the prevention or alleviation of MVO and CNR remain unmet goals in the therapy of STEMI that continue to be under intense research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.